vs
BIODESIX INC（BDSX）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是BIODESIX INC的4.9倍（$140.6M vs $28.8M）。VERACYTE, INC.净利率更高（29.3% vs -13.8%，领先43.1%）。BIODESIX INC同比增速更快（40.8% vs 18.5%）。VERACYTE, INC.自由现金流更多（$48.8M vs $692.0K）。过去两年BIODESIX INC的营收复合增速更高（39.3% vs 20.5%）
BIODESIX INC是一家专注于肿瘤与感染病领域的分子诊断企业，开发并商业化创新血液检测解决方案，主要服务北美地区的医疗机构、生物制药合作伙伴及患者，核心业务包括辅助临床决策的个性化医疗产品。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
BDSX vs VCYT — 直观对比
营收规模更大
VCYT
是对方的4.9倍
$28.8M
营收增速更快
BDSX
高出22.2%
18.5%
净利率更高
VCYT
高出43.1%
-13.8%
自由现金流更多
VCYT
多$48.1M
$692.0K
两年增速更快
BDSX
近两年复合增速
20.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $28.8M | $140.6M |
| 净利润 | $-4.0M | $41.1M |
| 毛利率 | — | 72.5% |
| 营业利润率 | -6.8% | 26.4% |
| 净利率 | -13.8% | 29.3% |
| 营收同比 | 40.8% | 18.5% |
| 净利润同比 | 51.8% | 704.8% |
| 每股收益（稀释后） | $-3.35 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDSXVCYT
| Q4 25 | $28.8M | $140.6M | ||
| Q3 25 | $21.8M | $131.9M | ||
| Q2 25 | $20.0M | $130.2M | ||
| Q1 25 | $18.0M | $114.5M | ||
| Q4 24 | $20.4M | $118.6M | ||
| Q3 24 | $18.2M | $115.9M | ||
| Q2 24 | $17.9M | $114.4M | ||
| Q1 24 | $14.8M | $96.8M |
净利润BDSXVCYT
| Q4 25 | $-4.0M | $41.1M | ||
| Q3 25 | $-8.7M | $19.1M | ||
| Q2 25 | $-11.5M | $-980.0K | ||
| Q1 25 | $-11.1M | $7.0M | ||
| Q4 24 | $-8.3M | $5.1M | ||
| Q3 24 | $-10.3M | $15.2M | ||
| Q2 24 | $-10.8M | $5.7M | ||
| Q1 24 | $-13.6M | $-1.9M |
毛利率BDSXVCYT
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% | ||
| Q1 24 | — | 64.5% |
营业利润率BDSXVCYT
| Q4 25 | -6.8% | 26.4% | ||
| Q3 25 | -32.4% | 17.4% | ||
| Q2 25 | -48.6% | -4.0% | ||
| Q1 25 | -50.9% | 2.5% | ||
| Q4 24 | -32.5% | 3.5% | ||
| Q3 24 | -47.3% | 10.4% | ||
| Q2 24 | -46.0% | 4.0% | ||
| Q1 24 | -74.4% | -4.8% |
净利率BDSXVCYT
| Q4 25 | -13.8% | 29.3% | ||
| Q3 25 | -40.0% | 14.5% | ||
| Q2 25 | -57.3% | -0.8% | ||
| Q1 25 | -61.8% | 6.2% | ||
| Q4 24 | -40.4% | 4.3% | ||
| Q3 24 | -56.5% | 13.1% | ||
| Q2 24 | -60.3% | 5.0% | ||
| Q1 24 | -91.9% | -1.9% |
每股收益（稀释后）BDSXVCYT
| Q4 25 | $-3.35 | $0.50 | ||
| Q3 25 | $-1.16 | $0.24 | ||
| Q2 25 | $-0.08 | $-0.01 | ||
| Q1 25 | $-0.08 | $0.09 | ||
| Q4 24 | $-5.02 | $0.07 | ||
| Q3 24 | $-1.40 | $0.19 | ||
| Q2 24 | $-0.08 | $0.07 | ||
| Q1 24 | $-0.14 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.0M | $362.6M |
| 总债务越低越好 | $50.0M | — |
| 股东权益账面价值 | $-2.5M | $1.3B |
| 总资产 | $87.5M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDSXVCYT
| Q4 25 | $19.0M | $362.6M | ||
| Q3 25 | $16.6M | $315.6M | ||
| Q2 25 | $20.7M | $219.5M | ||
| Q1 25 | $17.6M | $186.1M | ||
| Q4 24 | $26.2M | $239.1M | ||
| Q3 24 | $31.4M | $274.1M | ||
| Q2 24 | $42.2M | $235.9M | ||
| Q1 24 | $11.5M | $209.2M |
总债务BDSXVCYT
| Q4 25 | $50.0M | — | ||
| Q3 25 | $50.0M | — | ||
| Q2 25 | $50.0M | — | ||
| Q1 25 | $40.0M | — | ||
| Q4 24 | $40.0M | — | ||
| Q3 24 | $40.0M | — | ||
| Q2 24 | $40.1M | — | ||
| Q1 24 | $40.1M | — |
股东权益BDSXVCYT
| Q4 25 | $-2.5M | $1.3B | ||
| Q3 25 | $-1.7M | $1.3B | ||
| Q2 25 | $1.1M | $1.2B | ||
| Q1 25 | $11.1M | $1.2B | ||
| Q4 24 | $20.9M | $1.2B | ||
| Q3 24 | $27.9M | $1.2B | ||
| Q2 24 | $36.3M | $1.1B | ||
| Q1 24 | $-5.5M | $1.1B |
总资产BDSXVCYT
| Q4 25 | $87.5M | $1.4B | ||
| Q3 25 | $88.7M | $1.4B | ||
| Q2 25 | $87.7M | $1.3B | ||
| Q1 25 | $86.2M | $1.3B | ||
| Q4 24 | $97.2M | $1.3B | ||
| Q3 24 | $102.7M | $1.3B | ||
| Q2 24 | $115.8M | $1.2B | ||
| Q1 24 | $87.2M | $1.2B |
负债/权益比BDSXVCYT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 43.95× | — | ||
| Q1 25 | 3.62× | — | ||
| Q4 24 | 1.92× | — | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $778.0K | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $692.0K | $48.8M |
| 自由现金流率自由现金流/营收 | 2.4% | 34.7% |
| 资本支出强度资本支出/营收 | 0.3% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $-23.5M | $126.6M |
8季度趋势，按日历期对齐
经营现金流BDSXVCYT
| Q4 25 | $778.0K | $52.6M | ||
| Q3 25 | $-8.9M | $44.8M | ||
| Q2 25 | $-6.6M | $33.6M | ||
| Q1 25 | $-8.6M | $5.4M | ||
| Q4 24 | $-4.1M | $24.5M | ||
| Q3 24 | $-10.7M | $30.0M | ||
| Q2 24 | $-18.6M | $29.6M | ||
| Q1 24 | $-15.3M | $-9.0M |
自由现金流BDSXVCYT
| Q4 25 | $692.0K | $48.8M | ||
| Q3 25 | $-8.9M | $42.0M | ||
| Q2 25 | $-6.6M | $32.3M | ||
| Q1 25 | $-8.7M | $3.5M | ||
| Q4 24 | $-4.9M | $20.4M | ||
| Q3 24 | $-10.9M | $27.7M | ||
| Q2 24 | $-20.5M | $26.8M | ||
| Q1 24 | $-15.5M | $-11.1M |
自由现金流率BDSXVCYT
| Q4 25 | 2.4% | 34.7% | ||
| Q3 25 | -41.0% | 31.8% | ||
| Q2 25 | -33.1% | 24.8% | ||
| Q1 25 | -48.3% | 3.1% | ||
| Q4 24 | -24.2% | 17.2% | ||
| Q3 24 | -60.1% | 23.9% | ||
| Q2 24 | -114.3% | 23.4% | ||
| Q1 24 | -104.9% | -11.5% |
资本支出强度BDSXVCYT
| Q4 25 | 0.3% | 2.7% | ||
| Q3 25 | 0.2% | 2.1% | ||
| Q2 25 | 0.3% | 1.0% | ||
| Q1 25 | 0.4% | 1.6% | ||
| Q4 24 | 4.1% | 3.5% | ||
| Q3 24 | 1.3% | 1.9% | ||
| Q2 24 | 10.7% | 2.4% | ||
| Q1 24 | 1.6% | 2.2% |
现金转化率BDSXVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDSX
| Diagnostic Tests | $25.1M | 87% |
| Development Services | $3.6M | 13% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
